Overview

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial

Status:
Not yet recruiting
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.
Phase:
Phase 2
Details
Lead Sponsor:
Lumos Pharma